We would like to wish you a Happy Holidays and a wonderful New Year.
We look forward to seeing you in 2021!
AstraZeneca and The University of Oxford released results from its Phase 3 analysis of its COVID-19 vaccine candidate, AZD1222.
Drawn from two separate regimens, a half dose giving 90% efficacy and two full doses giving 62% efficacy, the pooled efficacy rate totalled 70%.Discover more.
New research has shed light on the role of antibodies and immune cells in the protection against SARS-CoV-2.
The findings have important implications for the development of SARS-CoV-2 vaccines and immune based therapeutics.
Almac Sciences.received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug, Remdesivir.
该药物是the first to receive approval of the FDA as a treatment for COVID-19.
From aligning ourselves with industry leading experts, Baker has a strong understanding of the wider industry and the complex problems that our customers face.
Visit our collaboration page on the website for more information.
Following on from last month’s Fact or Fiction focus on Neurodegenerative diseases, researchers at Case Western Reserve University School of Medicine identified a molecular pathway in Alzheimer’s disease.
The new discovery could lead to developments in therapeutics for the disease.
Did you see the review Dr. Ox shared on the role of hypoxia inducible factor-1 in cancer stem cells?
前往Twitterand see the latest content from Baker’s Director of Scientific Applications.
A recent study has shown that Aprotinin, a drug that is well known for reducing the risk of bleeding during surgery can stop the novel Coronavirus from entering and infecting host cells.
Researchers have said that biopharma firms have had to accelerate their adoption of new and innovative technologies since the COVID-19 pandemic began.
The development of SARS-CoV-2 vaccines and drugs combined have been major driving factors for these market changes.
View the first webinar of the series from Baker Ruskinn as Baker’s Director of Scientific Applications, Krista Rantanen Ph.D. presents Sir Peter Ratcliffe’s Nobel story.
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.